Answers are grounded in this paper and cite their sources.
Phase II trial demonstrates durable efficacy for all-oral ixazomib, pomalidomide, and dexamethasone in triple-class exposed multiple myeloma, suggesting a viable regimen for frail cohorts.
Multi-class upfront regimens for multiple myeloma (MM) have improved outcomes, yet many patients become either triple-class exposed (TCE) or refractory (TCR) early in their disease course. This is a phase II, investigator initiated, open-label, single-arm, prospective, multicenter study evaluating all-oral Ixazomib-pomalidomide- dexamethasone (IPd) regimen for TCE RRMM patients. Sixty-one patients were enrolled between March 1st 2021 and March 17th 2024. The median age was 74 (range: 53-89) years; 25 (41%) were ≥75 years old. Fiftyseven percent had high-risk cytogenetics (t(4;14), t(14;16), +1q21, del17p(. Twenty-six (43%) patients were frail. Refractoriness rates to bortezomib, lenalidomide and daratumumab were 51%, 85% and 96% respectively. Tripleclass refractory (TCR) rate was 39%. Ninety-seven percent of the patients had ≥1 treatment emergent adverse event (TEAE) and 67% had a TEAE grade ≥3. The rate of Gr ≥3 AE was not increased in frail vs. non-frail patients (p=0.43). Overall response rate (ORR) was 58% (22% very good partial response or better). TCR patients had an ORR of 46% vs. 68% for non-TCR patients (p=0.12). The median progression-free survival was 8.1 (95% CI 3.9-12.3) months and the median overall survival was 30.4 (95% CI 21.5-39.4) months. To conclude, the all-oral IPd regimen for TCE RRMM patients showed high response rates and a manageable safety profile, in a cohort enriched with TCR, elderly and frail patients. (NCT04790474).
No takes yet. Share an insight, caveat, or question.
Shragai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: